As a solution-oriented stakeholder in the Canadian healthcare environment, CHP Canada advocates for evidence-based policies that would enhance the contribution that consumer health products make to the health of Canadians and the sustainability of our healthcare system.
Canada lags behind the United States, United Kingdom and Australia by at least six to seven years when it comes to prescription to OTC switches, costing our healthcare system and our economy billions of dollars. Below is an illustration outlining the complex route for Rx-to-OTC switches in Canada.
Recent CHP Canada Submissions and Testimonies:
- The following CHP Canada formal submission on the 2016 Self-Care Framework. We continue to work with Health Canada and stakeholders to shape and evolve the regulatory proposal, as such our position continues to be refined.
- 2016 Self-Care Framework policy proposal
- News release – CHP Canada Applauds Health Canada’s Regulatory Proposal that Would Support Canadians Who Practice Self-Care
- Briefing Note Scheduling & Switch
- Canada’s Current Process for Switching Prescription Drugs to Non-Prescription Status (2016)
- CHP Canada’s Proposed Process for Switching Prescription Drugs to Non-Prescription Status in Canada (2016)
- Senate Standing Committee on Banking, Trade and Commerce, Study on Internal Barriers to Trade, CHP Canada testimony (May/16)
- House of Commons Standing Committee on Health, Pharmacare Study, CHP Canada testimony
- House of Commons Standing Committee on Finance-Pre Budget Consultations, CHP Canada testimony
- CHP Canada NAFTA letter_July 18 (Jul/17)
- USTR Nafta Letter Pharmaceutical Annex
- Attachment A_Healthy Growth Final Report
- Attachment B_EcoImpactsRxTtoOTC_RPT
- Attachment C_Briefing Note Data protection April 2017 Final
- Attachment D_2017-0531-Joint Comments on NAFTA Renegotiation
- Attachment E_CHPC CHPA RCC MRA briefing note FINAL
- CHPC CHPA RCC Submission 2016 FINAL – North American Trends in the Consumer Health Product Industry (Apr/16)